CAJ | 학술논문

目的探讨TAC方案在局部晚期乳腺癌患者术前新辅助化疗中的疗效.方法回顾性分析82例局部晚期乳腺癌患者临床资料,全部患者均接受TAC方案新辅助化疗,观察化疗后患者临床总有效率、近期毒副反应和手术情况.结果 82例乳腺癌患者9例病理完全缓解(11.0％),21例达到CR(25.6％),47例达到PR(57.3％),14例达到SD(17.1％),临床总有效率82.9％.毒副反应主要以骨髓抑制为主,白细胞减少发生率达81.7％.其他不良反应还包括消化道症状和肝功能损害、脱发等.所有患者经对症处理后均可耐受.结论 TAC方案新辅助化疗用于局部晚期乳腺癌患者可提高其治愈率,增加保乳机会.
목적 탐토TAC방안재국부만기유선암환자술전신보조화료중적료효.방법 회고성분석82례국부만기유선암환자림상자료,전부환자균접수TAC방안신보조화료,관찰화료후환자림상총유효솔、근기독부반응화수술정황.결과 82례유선암환자9례병리완전완해(11.0％),21례체도CR(25.6％),47례체도PR(57.3％),14례체도SD(17.1％),림상총유효솔82.9％.독부반응주요이골수억제위주,백세포감소발생솔체81.7％.기타불량반응환포괄소화도증상화간공능손해、탈발등.소유환자경대증처리후균가내수.결론 TAC방안신보조화료용우국부만기유선암환자가제고기치유솔,증가보유궤회.
Objective To investigate clinical effects of neoadjuvant chemotherapy of TAC scheme in breast cancer.Methods 82 patients with locally advanced breast cancer receiving neoadjuvant TAC chemotherapy program were retrospectively analyzed.The total efficiency,toxicity,and recent surgical cases were evaluated.Results There were 21 cases of CR in 82 cases with breast cancer,accounting for 25.6％,47 PR(57.3 ％),14 SD(17.1％),so the clinical total effective rate was 82.9％.The major toxic reactions was bone marrow suppression and neutropenia occurrence rate was 81.7％.Other adverse effects include gastrointestinal symptoms and liver dysfunction,and alopecia.All patients after symptomatic treatment can be tolerated.Conclusion TAC program neoadjuvant chemotherapy for locally advanced breast cancer patients can improve the cure rate,increase breast-conserving opportunities.